Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Life Sciences BPO Market Projected To Grow At A CAGR Of 21.5% Between 2013 And 2019

(click to enlarge)Click to enlarge

As the life sciences industry becomes increasingly competitive while being pressured by regulatory mandates, business process outsourcing (NYSE:BPO) is being considered as an effective way to improve operational performance.

The market for life sciences BPO is comprised of two distinct entities offering their services to biotech and pharmaceutical companies-Contract Research Organizations and Contract Manufacturing Organizations.

But what are the factors that have given rise to a demand for life science BPO services? The pharma industry is constantly grappling with patent expirations, a pressure to develop low-cost drugs, and the growing uncertainty in economic conditions. Companies in this domain thus need to approach their core operations with singular focus. This is where life science BPO enterprises come into the picture with their support services. Pharma companies outsource various functions and non-core operations to third parties with a view to streamlining their value chain and cutting costs.

These partnerships are usually forged in the form of long-term contracts and partnerships with CMOs and CROs. Through these partnerships, pharma companies share costs right from drug discovery and development to licensing to approvals with the CMOs and/or CROs.

Pharma companies are also experiencing effective outcomes via life science BPOs; the latter leverage their experience, trained professionals, and latest technology to the advantage of the former.

On the other hand, life-science BPOs too have been driven by the pressure to compete and achieve profitability. They try to accomplish this by introducing novel strategies to offer their clients a competitive advantage. According to a market research report published by U.S.-based market research firm Transparency Market Research, the global life sciences BPO market is projected to record a compounded annual growth rate (OTCPK:CAGR) of 21.5% between 2013 and 2019. Experts predict a healthy growth rate thanks to factors such as increased R&D investments by pharmaceutical companies, a spike in the demand for generic drugs, as well as a myriad of block buster drugs nearing the end of their patents. Other factors that have created a favorable environment for life science BPO include stringent regulatory mandates and government pressure to develop affordable drugs.

The Contract Manufacturing Organizations Market

According to the market research report published by Transparency Market Research, the CMO life science services outsourcing currently holds the largest share in the Life Sciences BPO market. The growth in healthcare costs has subsequently caused an increased generic drug demand, which has in turn led to a spike in the demand for the services of pharmaceutical outsourcing enterprises. Moreover, most CMOs have full-fledged R&D centers that employ novel technologies to give their clients an edge.

The market for active pharmaceutical ingredients (NYSEMKT:API) is the largest within the CMO segment. With mounting regulatory compliance and stringent approval parameters, the outsourcing of manufacturing activities to CMOs has received a boost.

At a time when manufacturers are striving to stay abreast of the latest regulatory mandates and industry breakthroughs, continually investing in facility upgrades might not be possible. This is another factor that can be attributed to the surge in demand for outsourcing partners as manufacturers do not possesses every required technology or expertise in-house. In such scenarios, outsourcing not only gives them access to the latest manufacturing technologies, but also proves to be a cost effective strategy.

The Contract Research Organizations (CRO) Market

Over the past decade, there has been considerable growth in the outsourcing services offered by CROs. Many pharmaceutical companies have been struggling to find a balance between mounting research costs and profitability. This has led many of these firms to turn towards CROs as a feasible option. The vendors operating in the market currently offer a combination of various services such as research, regulatory co-ordination services, data management, website management, medical writing, protocol development and others.

In 2012, the largest segment within this market was drug discovery. A report by Transparency Market Research however projects that between 2013 and 2019, the highest growth will be seen in the clinical data management BPO services at the rate of 17.3%.

Growth Projections

It is estimated that the Life Sciences BPO Market will be worth USD 596 billion worldwide by 2019, according to the Transparency Market Research report. And, while North America held the largest share in this market in 2012 with a worth of USD 28.4 billion, future growth is expected to be the highest in the Asia Pacific region with an approximate growth rate of 21.2% driven by various factors such as low cost of labor, availability of a talent pool, a large patient population, and comparatively favorable regulatory policies.

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.

Stocks: BPO, CAGR